Search results for "Administration"

showing 10 items of 5106 documents

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controll…

2009

Objective To assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles. Design Single-center, randomized, single-blind, placebo-controlled trial. Setting University-affiliated infertility clinic, between February 2005 and December 2007. Patient(s) Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication. Intervention(s) Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n = 172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time. Main Outcome Measure(s) Pregnancy rate was the primary outcom…

AdultMalemedicine.medical_specialtyTime FactorsPregnancy Ratemedicine.medical_treatmentLuteal phaseDrug Administration Schedulelaw.inventionMiscarriageGonadotropin-Releasing HormonePlacebosRandomized controlled triallawPregnancyMedicineHumansSingle-Blind MethodEmbryo ImplantationInsemination ArtificialGynecologyPregnancyTriptorelin Pamoatebusiness.industryObstetricsArtificial inseminationUterusPregnancy OutcomeObstetrics and GynecologyFertility Agents Femalemedicine.diseaseTriptorelinPregnancy rateReproductive MedicineGestationFemalebusinessAlgorithmsmedicine.drugFertility and sterility
researchProduct

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

2012

A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

AdultMalemedicine.medical_specialtyTime FactorsPyridonesHeart VentriclesThalassemiaDeferoxamineIron Chelating AgentsModels BiologicalDrug Administration Schedulechemistry.chemical_compoundInternal medicineHumansMedicineLeft ventricular ejectionDeferiproneIn patientRetrospective StudiesUltrasonographyEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeHematologymedicine.diseasehumanitieschemistryCardiologyDrug Therapy CombinationFemaleThalassemia major Left ventricular ejection fraction Deferiprone sequential deferiprone-deferoxamine Echocardiography ChelationbusinessDeferiproneAmerican Journal of Hematology
researchProduct

Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels

2002

In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200–600 mg/day or flupenthixol 5–15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of t…

AdultMalemedicine.medical_specialtyTime FactorsThyrotropin-releasing hormoneFlupenthixolDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansAmisulprideBenzamideThyrotropin-Releasing HormoneBiological PsychiatryMiddle AgedProlactinProlactinFlupentixolFlupenthixolPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologychemistrySchizophreniaFemaleAmisulprideSulpiridePsychologyAntipsychotic Agentsmedicine.drugHormoneNeuropsychobiology
researchProduct

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria pati…

2002

Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). Methods: Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (fiv…

AdultMalemedicine.medical_specialtyTime FactorsUrticariaUrinary systemImmunologyMethylhistamineProvocation testAdministration OralUrinePlaceboGastroenterologyBronchoconstrictor AgentsDrug HypersensitivityExcretionchemistry.chemical_compoundDouble-Blind MethodSodium BenzoateInternal medicineSodium GlutamatemedicineHumansSulfitesImmunology and AllergyCyclooxygenase InhibitorsTartrazineLeukotriene E4CreatinineAspirinDose-Response Relationship DrugAngioedemabusiness.industryMethylhistaminesMiddle AgedEndocrinologyItalychemistryChronic DiseaseFemaleFood AdditivesControlled Clinical Trials as Topicmedicine.symptombusinessBiomarkersAllergy
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

Treatment of Ménière's disease by low-dosage intratympanic gentamicin application: effect on otolith function.

2007

Objectives: The intratympanic application of a low dosage of gentamicin is increasingly favored as treatment for Meniere's disease. While posttreatment observations have confirmed a long-term success of the therapy of vertigo attacks, clear differences in the posttreatment recovery interval can be observed. In addition to differences in central-vestibular compensation, the degree of peripheral vestibular damage, i.e., to the saccule, utricle, and semicircular canal ampullae, varies among patients. This study provides comprehensive pre- and posttreatment results from unilateral functional tests of the individual vestibular receptors and of the cochlea in patients with Meniere's disease. Stud…

AdultMalemedicine.medical_specialtyTympanic MembraneVestibular evoked myogenic potentialAdministration TopicalOtolithic MembraneUtricleVertigootorhinolaryngologic diseasesmedicineHumansProspective StudiesMeniere DiseaseAntibacterial agentAgedVestibular systemSemicircular canalbiologyDose-Response Relationship Drugbusiness.industryElectromyographymedicine.diseasebiology.organism_classificationSurgeryAnti-Bacterial Agentsmedicine.anatomical_structureTreatment OutcomeOtorhinolaryngologyAnesthesiaEvoked Potentials AuditoryFemalesense organsSacculeGentamicinsbusinessMeniere's diseaseFollow-Up StudiesThe Laryngoscope
researchProduct

The tongue as an alternative donor site for graft urethroplasty: A pilot study

2006

Purpose: Urethroplasty with a buccal mucosal graft provides excellent clinical results but it may also cause oral complications in some cases. The mucosa covering the lateral and under surface of the tongue is identical in structure with that lining the rest of the oral cavity. We evaluated LMGs for urethroplasty.Materials and Methods: From January 2001 to September 2004, 8 men 34 to 65 years old (mean age 46.1) with urethral strictures 1.5 to 4.5 cm long were selected for 1-stage dorsal onlay urethroplasty. The site of the harvest graft was the lateral mucosal lining of the tongue. Postoperatively all patients were followed with urethrography, uroflowmetry, cystourethrography and flexible …

AdultMalemedicine.medical_specialtyUrethral strictureUrologyUrethroplastymedicine.medical_treatmentTransplantsPilot ProjectsTransplantTongueUrethraTonguemedicineHumansAlternative donorUrethral strictureAgedbusiness.industryMouth MucosaMucous membraneMucous membraneBuccal administrationMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureUrethraMucosal graftUrethra; Urethral stricture; Tongue; Mucous membrane; TransplantsUrologic Surgical Proceduresbusiness
researchProduct

Pharmacokinetics of atenolol in relation to renal function

1981

The plasma levels and urinary excretion of carteolol and its main metabolites 8-hydroxycarteolol and carteolol glucuronide were investigated in 6 healthy subjects and 9 patients with varying degrees of renal impairment following a single oral dose of 30 mg carteolol hydrochloride. In healthy subjects the half-life of carteolol was 7.1 h. 63% of the administered dose was recovered unchanged in urine, and in all 84% was excreted by the kidneys. The renal clearance of carteolol was 255 ml/min. In chronic renal failure (CRF) the terminal half-life was increased to a maximum of 41 h. Both the elimination rate constant and renal clearance were closely related to the creatinine clearance. In CRF t…

AdultMalemedicine.medical_specialtyUrologyAdministration OralRenal functionCarteolol HydrochloridePropanolamineschemistry.chemical_compoundPharmacokineticsElimination rate constantRenal DialysisInternal medicinemedicineHumansPharmacology (medical)CarteololAgedPharmacologyKidneyCreatinineMaintenance dosebusiness.industryGeneral MedicineMiddle AgedKineticsEndocrinologymedicine.anatomical_structureAtenololchemistryInjections IntravenousFemaleKidney DiseasesbusinessGlomerular Filtration Ratemedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

2015

<b><i>Introduction:</i></b> The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. <b><i>Materials and Methods:</i></b> Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. <b><i>Results:</i></b> A total of 411 patients we…

AdultMalemedicine.medical_specialtyUrologyInternational CooperationAntineoplastic AgentsSettore MED/24 - UrologiaMedication AdherenceSocial lifeCohort StudiesRecurrenceInternal medicinemedicineHumansAgedBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgeryClinical PracticeRegimenAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsTreatment interruptionToxicityBCG VaccineDisease ProgressionIntravesical bcgPatient ComplianceFemalenon muscle invasive bladder cancer Bacillus Calmette Guèrin intravesical instillation immunotherapy compliance toxicityNeoplasm Recurrence LocalbusinessCohort studyUrologia internationalis
researchProduct